NASDAQ · Biotechnology

Kyverna Therapeutics, Inc. (KYTX) Stock

$6.39 +3.40% NASDAQ: KYTX Healthcare

Valuation

MetricValue
Price$6.39
Market Cap$388.48M
P/E Ratio-2.33
P/B Ratio2.52
P/S Ratio0.00
EPS (TTM)$-3.64
52-Week High$13.67
52-Week Low$5.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-81.91%
ROA-69.44%
ROCE-80.67%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.20
Current Ratio7.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$6.0M$7.0M$0$0$0
Operating Profit$-26.0M$-29.0M$-62.0M$-143.0M$-170.0M
Net Profit$-26.0M$-29.0M$-60.0M$-127.0M$-161.0M
EPS$-1.02$-1.12$0.00$-3.33$-3.64
Op Margin-465.8%-418.3%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$85.0M$67.0M$75.0M$305.0M$294.0M
Total Liabilities$132.0M$141.0M$26.0M$38.0M$62.0M
Cash$76.0M$38.0M$35.0M$97.0M$124.0M
Borrowings$6.0M$11.0M$9.0M$8.0M$29.0M

Latest News

Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond Insider Monkey · Jul 9, 2026 Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition GlobeNewswire · Jun 22, 2026 FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases Exec Edge · Jun 9, 2026 Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? Motley Fool · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-22.0M$-36.0M$-52.0M$-114.0M$-154.0M
Investing Cash Flow$-3.0M$-15.0M$-9.0M$-163.0M$40.0M
Financing Cash Flow$0$0$-2.0M$-3.0M$0
Net Cash Flow$49.0M$-38.0M$-3.0M$62.0M$27.0M
Free Cash Flow$-23.0M$-37.0M$-53.0M$-116.0M$-154.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.11
EV / EBITDA-2.79
FCF Yield-38.34%
Quick Ratio9.06
Interest Coverage-88.69
Return 1Y68.36%
Return 3Y—
Return 5Y—

Ownership

Insiders Held7.10%
Institutions Held74.72%
Institutions Float Held80.43%
Institutional HolderSharesReport Date
GordonMD Global Investments LP4,244,8182026-03-31
Gilead Sciences Inc4,126,1192026-03-31
Bain Capital Life Sciences Investors, LLC3,110,0002026-03-31
AIGH Capital Management LLC2,000,0002026-03-31
Deerfield Management Company, L.P2,000,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. is led by CEO Warner Biddle, employs 112 people, headquartered in US, publicly traded since 2024.

Kyverna Therapeutics, Inc. (KYTX) stock trades at $6.39 with a market capitalization of $388.48M. The stock is valued at a price-to-earnings (P/E) ratio of -2.33, price-to-book of 2.52, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.30 and $13.67, and currently trades 53.3% below its 52-week high.

On profitability, Kyverna Therapeutics, Inc. generates a return on equity (ROE) of -81.91%, return on capital employed of -80.67%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides